Table 2

Serological response following three-dose vaccination in patients

Anti-Spike antibody level BAU/mL, median (IQR)
Patients overall third dose5720 (2138–8732)
Diagnoses
 Rheumatoid arthritis5993 (2407–9855)
 Spondyloarthritis4549 (1897–8358)
 Psoriatic arthritis6891 (3065–9405)
 Ulcerative colitis5513 (2016.5–8130)
 Crohn’s disease4978 (1877–7929)
Medication
 Tumour necrosis factor inhibitor, monotherapy*5174 (2000–7856)
 Tumour necrosis factor inhibitor combination therapy†4252 (1475–8322)
 Methotrexate7464 (4239–10685)
 Vedolizumab7758 (5033–9606)
 Janus kinases inhibitor2527 (895–6439)
 Tocilizumab, ustekinumab and secukinumab7083 (4803–9569)
 Abatacept4547 (1551–6613)
 Other‡9625 (7647–10190)
Vaccines
 BNT162b24628 (1694–7719)
 mRNA-12736610 (3764–10084)
 Combination of vaccines§7154 (2810–9797)
Other factors
 Age groups
 Age <30 years7158 (3337–9465)
 Age 30–65 years5784 (2270–8701)
 Age >65 years4758 (1626–8331)

  • *Tumour necrosis factor inhibitors: infliximab, etanercept, adalimumab, golimumab, certolizumab pegol.

  • †Combination therapy: tumour necrosis factor inhibitor in combination with either methotrexate, sulfasalazine, leflunomide or azathioprine.

  • ‡Drugs with less than 10 patients included: sulfasalazine, leflunomide, azathioprine, risankizumab, prednisolone monotherapy.

  • §Combination of the following vaccines: ChAdOx1, BNT162b2, mRNA-1273

  • BAU, binding antibody unit; IQR, Inter quartile range.